Since 2007, I have been working in the research area of neurology, nanotechnology and nanomedicine. In the initial states of my career, I developed methods to enhance the stability of nanovehicles and developed various types of polymeric nanoparticles to treat and diagnose cerebral amyloid angiopathy. Other previous research projects that I have completed include, evaluating the effect of insulin on amyloid clearance from the Alzheimer’s disease brain and evaluating the effect of age on insulin trafficking into the central nervous system. Prior to joining RFUMS, I worked at the nanocore facility at the U.S. Food and Drug Administration, National Center for Toxicological Research on a research project targeted toward providing (FDA) reviewers with the necessary information to build more clinically relevant standards for FDA-regulated nanoparticulate drug products. My research areas of interest are nanotechnology, nanomedicine, delivery of therapeutic and diagnostic agents to the central nervous system, novel strategies to improve the uptake of nanoparticles at the blood brain barrier and pharmacokinetic data analysis and modeling.
